by Ingredion

Ingredion invests in India-Based Mannitab Pharma Specialities

Ingredion has taken a majority position in Mannitab Pharma Specialities, a manufacturer of specialty mannitol.

Table of contents

Ingredion Incorporated (NYSE: INGR), a leading global provider of ingredient solutions to the food and beverage industry, today announced that it has taken a majority position in Mannitab Pharma Specialities, a manufacturer of specialty mannitol, including direct compression grades used in high-value drug formulations.

Mannitab was started by M.B. Sugars & Pharmaceuticals Private Limited, a leading supplier of specialty sugars to the pharmaceutical industry in India, and was spun off as a separate entity in 2022. M.B. Sugars will continue to remain an operating partner in Mannitab, while Ingredion’s investment will further expand Mannitab’s manufacturing capacity and global reach.

“Mannitab’s specialty mannitols, particularly the direct compression grades, complement Ingredion’s excipients portfolio of starches, mannitol powder, and dextrose,” said Sriprakash Krishnan, Ingredion’s general manager of APAC pharma.

“We look forward to partnering with Ingredion to expand our supply and service capabilities to our customers from our facilities in India,” said Rushabh Lodha, one of the founders of Mannitab Pharma Specialities and MB Sugar pharma businesses. To help ensure synergies and business continuity, both Krishnan and Lodha will serve as co-business leaders of Mannitab.

“India is a very attractive and growing market with a strong manufacturing base that allows us to support and supply our customers,” said Ingredion’s Valdirene Bastos-Evans, senior vice president and president of Asia-Pacific and global head of nutrition, health & wellness. “This investment follows our acquisition of Amishi Drugs & Chemicals (AD&C) in the first half of 2022. These combined acquisitions will enhance Ingredion’s offerings to pharma and nutraceutical customers.” 

About Ingredion Pharma & Nutraceuticals

Ingredion Incorporated (NYSE: INGR) is a global innovative ingredient solutions provider serving customers for more than 100 years in more than 120 countries. For pharma & nutraceuticals, the Company partners with formulators seeking excipients to enhance the performance of formulations and overcome their technical challenges. The Company’s pharma solutions include binders, fillers, super-disintegrants, lubricants, gelatine replacers for softgel encapsulation, viscosifiers, and parenteral APIs for different dosage forms. In line with current and emerging trends and regulations, the Company is in the continuous transformation to combine CGMP facilities, regulatory assistance, worldwide presence, and collaborative technical support to be a trusted formulation problem-solving partner to its customers.

About M.B. Sugars

M.B Sugars & Pharmaceuticals Private Limited (“M B Sugars”) with over 3 decades of legacy is engaged in the business of specialty ingredients for the pharmaceutical, food, and nutraceutical Industries. M B Sugars was established in the 1990s with the intent to provide high-quality import substitutes to the Indian Pharmaceutical Industry. M B Sugars has since stuck to this vision and developed several high-quality excipients in its state of art cGMP compliant manufacturing plant in Maharashtra, India. The company has been a leader in pharma-grade sucrose and sugar spheres. M B Sugars has been a trusted partner for over 200 pharmaceutical companies pan India and has a presence in more than 30 countries.

About Mannitab Pharma Specialities

Mannitab Pharma Specialities Private Limited (“Mannitab Pharma Specialities”) was incorporated in 2022 and the Mannitol division of M B Sugars was spun off into Mannitab Pharma Specialities. Mannitab Pharma Specialities will be leveraging the combined strengths of Ingredion and M B Sugars in expanding its reach and enhancing customer service.